PT  - JOURNAL ARTICLE
AU  - Marconi, Vincent C.
AU  - Kilcoyne, Adrian
AU  - Cerasoli, Franklin
AU  - Polk, Christopher
AU  - Lewis, Meghan
AU  - Burger, Charles D.
AU  - Jordan, Edward
AU  - Durrant, Cameron
AU  - Chappell, Dale
AU  - Temesgen, Zelalem
TI  - LENZILUMAB OUTCOMES ACCORDING TO RACE OF COVID-19 PARTICIPANTS IN THE LIVE-AIR PHASE 3 TRIAL
AID  - 10.1101/2022.08.18.22278867
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.08.18.22278867
4099  - http://medrxiv.org/content/early/2022/08/21/2022.08.18.22278867.short
4100  - http://medrxiv.org/content/early/2022/08/21/2022.08.18.22278867.full
AB  - RATIONALE The hyperinflammatory immune response of COVID-19, in part orchestrated by granulocyte-macrophage colony-stimulating factor (GM-CSF) can lead to respiratory failure and death with disparities in outcomes between racial subgroups. In the LIVE-AIR trial, the GM-CSF neutralizing antibody lenzilumab improved survival without mechanical ventilation (SWOV) in COVID-19.OBJECTIVE An analysis of outcomes was performed to determine differences between Black/African American (B/AA) and White participants in LIVE-AIR.METHODS LIVE-AIR was a phase 3, randomized, double-blind, placebo-controlled trial. Participants hospitalized with COVID-19 pneumonia were randomized 1:1 to receive lenzilumab (1800 mg total) or placebo in addition to standard of care, including remdesivir and/or corticosteroids.MEASUREMENTS AND MAIN RESULTS Lenzilumab, compared to placebo, numerically improved the likelihood of SWOV (primary endpoint) in B/AA (n=71; 86.8% vs 70.9%; HR, 2.68; 95% confidence interval [CI], 0.88-8.11; p=0.0814) and White (n=343; 85.1% vs 80.8%; HR, 1.41; 95%CI, 0.85-2.35, p=0.182) participants. A statistically significant improvement in SWOV was observed in B/AA (HR: 8.9; 95%CI: 1.08, 73.09; p=0.0418) and White (HR: 2.32; 95%CI: 1.17, 4.61; p=0.0166) participants with baseline CRP<150 mg/L. Lenzilumab numerically, but not statistically, improved secondary endpoints of IMV, ECMO or mortality; ventilator-free days; ICU days and time to recovery in either race while ventilator-free days, ICU days, and time to recovery were statistically improved in B/AA participants with baseline CRP<150 mg/L. Lenzilumab was well tolerated without differences in serious adverse events regardless of race.CONCLUSION Lenzilumab significantly improved SWOV and some key secondary outcomes in B/AA COVID-19 participants with baseline CRP<150 mg/L. NCT04351152Competing Interest StatementVCM has received investigator-initiated research grants (to the institution) and consultation fees (both unrelated to the current work) from Eli Lilly, Bayer, Gilead Sciences and ViiV; AK, CD, EJ, and DC are employees of Humanigen, Inc., FC is third-party agency consultants to Humanigen, Inc; CP is a paid consultant to Gilead. CDB and ML have no conflicts of interest. ZT has received research support from Humanigen, Inc, unrestricted education support from Gilead, ViiV, and Merck (all to the institution).Clinical TrialNCT04351152Funding StatementAll aspects of the LIVE-AIR trial and preparation of this manuscript were supported by Humanigen, IncAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with the Good Clinical Practice guidelines of the International Council for Harmonization E6 and the principles of the Declaration of Helsinki. Central IRB (ADVARRA) approval was obtained in addition to local IRB approval at each participating institution as appropriate for all aspects of this company-sponsored phase 3 clinical trial. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript